Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879233 | 1.00 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3877913 | 0.90 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3877916 | 0.90 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3878914 | 0.86 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3878919 | 0.86 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3889452 | 0.85 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3889455 | 0.85 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3884933 | 0.80 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3884925 | 0.80 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11LCK | |
| SCHEMBL3881152 | 0.77 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | claimed |
| JP-2007510739-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1682551-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005047287-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | claimed |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | CLARK MICHAEL PHILIP | 2009-03-12 | — | — | US | disclosed |
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1682551-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047287-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | MAPK14 922/4885MAPK13 2033/4885MAPK12 2453/4885 |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | MAPK14 922/4885MAPK13 2033/4885MAPK12 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.